NOT-CA-01-001: ADDENDUM: CANCER CARE OUTCOMES RESEARCH AND SURVEILLANCE CONSORTIUM (RFA-CA-01-013)

Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health^®


ADDENDUM: CANCER CARE OUTCOMES RESEARCH AND SURVEILLANCE 
CONSORTIUM (RFA-CA-01-013)
		 
Release Date:  October 4, 2000

NOTICE:  CA-01-001

National Cancer Institute

This addendum is to inform potential applicants of three changes to RFA-CA-01-
013 entitled  Cancer Care Outcomes Research and Surveillance Consortium  
released August 24, 2000. 

First, a change with regard to minimum enrollment for each Primary Data 
Collection and Research (PDCR) site applicant is as follows:
     
1. Under SPECIAL REQUIREMENTS, Terms and Conditions of Award, Part B, Primary 
Data Collection and Research (PDCR) site responsibilities, the minimum 
number of patients is changed from 1,000 to 700 patients per cancer (lung 
and colorectal).  
2. Under APPLICATION PROCEDURES, Specific Instructions for PDCR sites, 
instruction number 2, the minimum number of patients to be enrolled is 
changed from 1,000 to 700 patients per cancer over a two year accrual 
period.  As before, applicants are not required to participate in studies 
of both lung and colorectal cancer.  
3. Under REVIEW CONSIDERATIONS, Specific Review Criteria: PDCR Sites, number 
2a, the minimum number of cases is changed from 1,000 per cancer type to 
700 per cancer type. 

Second, given the reduction of the minimum sample size allowed, all PDCR site 
applicants are encouraged to target 1,000 patients per cancer type, if 
resources permit, in order to achieve the sample size objective of 6,000 
patients per cancer within the CanCORS Consortium as a whole.  

The third change is a clarification of the definition of the Principal 
Investigator under the section entitled RESEARCH OBJECTIVES, Definitions.  
Currently, the definition reads:  
 Each institution may have more than one CanCORS PI, and a single person may 
be the PI for an application that includes both lung and colorectal cancer.   

The revised statement reads:  
 Since there must be a single PI for each application, one person will be the 
PI for those applications that include both lung and colorectal cancer.  On 
such applications, the PI may designate a second individual to be a full 
participating member of the CanCORS Steering Committee.  

All other provisions of CA-01-013 remain unchanged.  The complete RFA can be 
found at http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-01-013.html  

INQUIRIES

Inquiries are encouraged, and the opportunity to clarify issues and answer 
questions is welcome.  Inquiries may be directed to:

Arnold L. Potosky, Ph.D.
Division of Cancer Control and Population Sciences
National Cancer Institute
6130 Executive Boulevard, Room 4005, MSC 7344
Bethesda, MD  20892-7344
Telephone:  (301) 496-5662
FAX:  (301) 435-3710
Email:  [email protected]
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices